|
Demographics
|
RRT initiation
|
Death before RRT initiation
|
|---|
|
SHR
|
95% CI
|
P-value
|
SHR
|
95% CI
|
P-value
|
|---|
|
Age (years)
|
|
<65
|
1.00
|
ref
| |
1.00
|
ref
| |
|
65–75
|
0.64
|
0.57–0.72
|
<0.01
|
2.48
|
2.07–2.97
|
<0.01
|
|
>75
|
0.449
|
0.40–0.51
|
<0.01
|
5.47
|
4.61–6.49
|
<0.01
|
|
Women
|
0.72
|
0.66–0.80
|
<0.01
|
0.77
|
0.70–0.85
|
<0.01
|
|
Primary renal disease
|
|
Hypertensive kidney disease
|
1.00
|
ref
| |
1.00
|
ref
| |
|
Diabetes nephropathy
|
1.21
|
1.03–1.41
|
0.020
|
0.57
|
0.45–0.72
|
<0.01
|
|
Glomerulonephritis
|
1.04
|
0.91–1.19
|
0.59
|
0.78
|
0.67–0.90
|
<0.01
|
|
Other specified disease
|
0.67
|
0.57–0.78
|
<0.01
|
1.06
|
0.94–1.19
|
0.36
|
|
Unknown
|
1.00
|
0.97–1.04
|
0.87
|
1.20
|
1.17–1.24
|
<0.01
|
|
Fast progressor (above 18.7% decline/year)
|
2.24
|
2.00–2.51
|
<0.01
|
1.27
|
1.13–1.43
|
<0.01
|
|
CKD stagea
|
|
G3b
|
1.00
|
ref
| |
1.00
|
ref
| |
|
G4
|
2.04
|
1.52–2.75
|
<0.01
|
0.94
|
0.80–1.09
|
0.40
|
|
G5
|
4.05
|
2.89–5.67
|
<0.01
|
0.94
|
0.75–1.19
|
0.61
|
|
Charlson Score above kidney disease (per 1 unit increase)
|
1.15
|
1.04–1.28
|
0.01
|
1.06
|
0.95–1.17
|
0.31
|
|
Body Mass Index (kg/m2)
|
|
<18.5
|
1.08
|
0.72–1.62
|
0.72
|
1.39
|
0.98–1.96
|
0.06
|
|
18.5–25
|
1.00
|
ref
| |
1.00
|
ref
| |
|
25–30
|
0.91
|
0.81–1.02
|
0.11
|
0.96
|
0.85–1.07
|
0.46
|
|
>30
|
0.90
|
0.80–1.02
|
0.11
|
0.86
|
0.76–0.98
|
0.02
|
- Chronic Kidney Disease (CKD) Renal replacement therapy (RRT), Sub-hazard ratio (SHR) Confidence interval (CI). All variables, estimates are adjusted for all other variables, eGFR after the initial follow-up, current medication, laboratory data, hospital status, region and diet
-
aafter the initial one-year baseline period when progression rate was estimated
